Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro

By K. Ono, K. Hasegawa, H. Naiki, M. Yamada. Journal of Neuroscience Research, 2004

1,040 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials (2008, neutral): “-amyloid fibrils (fAbeta) and promoted their destabilization (184).”
Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. (2011, background): “Curcumin (in vitro) has also been observed to inhibit the metabolism of amyloid precursor protein (220) and dose dependently inhibit amyloid-b fibril formation and extension, as well as destabilizing existing fibrils (221).”
Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy (2007, background): “Nanocurcumin opens up avenues for systemic therapy of human cancers, as well as other human maladies like Alzheimer disease [48-51] and cystic fibrosis [52-54], wherein the beneficial effects of curcumin have been propounded.”
Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model (2007, background): “This can be attributed to the capacity of curcumin to disaggregate and inhibit Ab aggregation as previously described in vitro (Ono et al. 2004; Yang et al. 2005).”
Antioxidant and antimicrobial activities of rosemary extracts linked to their polyphenol composition (2006, background): “Recently, it was reported that this compound could be a therapeutic agent in Alzheimer’s disease treatment [11].”